Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Sclerosis (MS) Clear all
Completed Phase 2 Interventional

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

NCT00071838
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Daclizumab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 23, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)

NCT06463743
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
metformin, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
55 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 3 Interventional

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

NCT01844232
View directory record Official record
Conditions
Multiple Sclerosis, Spasticity
Interventions
arbaclofen
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Gilbert, Arizona • Phoenix, Arizona • Pasadena, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 23, 2026, 2:42 PM EDT
Not listed Not applicable Interventional

The SEMS Project: Staying Employed With MS

NCT03647904
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
SEMS Project
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Not applicable Interventional Results available

Electric Stimulation of the Eye to Improve Vision After Trauma

NCT02019927
View directory record Official record
Conditions
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), Trauma, Multiple Sclerosis (MS)
Interventions
Transcorneal Electrical Stimulation, Sham
Device
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 23, 2026, 2:42 PM EDT
Active, not recruiting Phase 2 Interventional

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

NCT00716066
View directory record Official record
Conditions
Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
Interventions
Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation
Biological · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 71 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 23, 2026, 2:42 PM EDT
Recruiting Not applicable Interventional

Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients

NCT07392879
View directory record Official record
Conditions
Progressive Multiple Sclerosis, Depression
Interventions
Virtual Reality, Standard care
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 23, 2026, 2:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

NCT03109288
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cilostazol, Leucovorin, Pirfenidone, Dantrolene, Pioglitazone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya

NCT02141022
View directory record Official record
Conditions
Multiple Sclerosis, Cognitive Deficits, Gilenya Modifying Therapy for MS
Interventions
plasticity-based computerized cognitive remediation program, Gileyna
Other · Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Sep 23, 2026, 2:42 PM EDT
Not listed Phase 4 Interventional

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

NCT04048577
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Dosing Interruption of Natalizumab
Drug
Lead sponsor
Berkovich, Regina MD, PhD Inc.
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 23, 2026, 2:42 PM EDT
Recruiting Not applicable Interventional

A Study of the MIND Diet for Persons With Multiple Sclerosis

NCT06992115
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet, Small Group
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Waking Hypnosis in the Treatment of MS-related Fatigue

NCT04429789
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Active-Alert Hypnosis, Traditional Hypnosis
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

NCT00648908
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Emotion Regulation Skills Training for Individuals With MS and Their Support Partners

NCT03934489
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
PERSIST, Facilitated Peer Support
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 23, 2026, 2:42 PM EDT
Completed No phase listed Observational

A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years

NCT01847287
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

NCT03972306
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Ocrelizumab, rHuPH20
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
18
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Alexandria, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 1Phase 2 Interventional

Comparison of the Efficacy and Mechanisms for MBCT and CT for Multiple Sclerosis (MS) Chronic Pain

NCT02012439
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Mindfulness Based Cognitive Therapy, Cognitive Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

NCT01764737
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
VX15/2503, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Cullman, Alabama • Aurora, Colorado • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Sep 23, 2026, 2:42 PM EDT
Not listed Not applicable Interventional

Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses

NCT01900093
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Acthar Gel
Drug
Lead sponsor
Aaron Miller
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

Aspirin for Exercise in Multiple Sclerosis (ASPIRE)

NCT03824938
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Aspirin 650mg Oral Capsule, Acetaminophen Tablet 650mg, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 23, 2026, 2:42 PM EDT
Completed No phase listed Observational

A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

NCT01541618
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
MSDX Complex-1 Biomarker test
Other
Lead sponsor
MSDx, Inc.
Industry
Eligibility
45 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 4 Interventional Results available

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

NCT00536120
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BG00002 (natalizumab), keyhole limpet hemocyanin (KLH), tetanus diphtheria toxoid vaccine (Td)
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Fullerton, California • Centennial, Colorado • Farmington Hills, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Sep 23, 2026, 2:42 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

NCT04203498
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Port Charlotte, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 23, 2026, 2:42 PM EDT
Withdrawn Phase 4 Interventional

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS

NCT02675413
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Dimethyl Fumarate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
St Louis, Missouri • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 23, 2026, 2:42 PM EDT